In 2024, Genetron Health Bridge, a leading Chinese vascular intervention medical device company, announced the completion of its full acquisition of Optimed, a renowned German peripheral vascular intervention device manufacturer. This strategic acquisition marks a significant step in Genetron Health Bridge’s accelerated global expansion and enhanced international competitiveness. Founded in 1985 and headquartered in Tuttlingen, Germany, Optimed specializes in the development and manufacturing of high-end devices—including catheters, balloons, and stents—for the treatment of peripheral vascular diseases. The company boasts a strong distribution network and solid brand reputation across Europe. Through this acquisition, Genetron Health Bridge gains access to Optimed’s mature R&D platform and CE-certified product portfolio, significantly strengthening its commercial capabilities in Europe and globally. Furthermore, synergies in technology, supply chain, and clinical resources between the two companies are expected to drive joint innovation and accelerate the internationalization of China-developed high-end medical devices. Genetron Health Bridge stated it will continue pursuing a dual-pronged strategy of ‘in-house R&D plus global M&A’ to deepen its global operations and deliver safer, more effective vascular intervention solutions to patients worldwide.
2024年，中国领先的血管介入医疗器械企业归创通桥宣布完成对德国知名外周血管介入器械公司Optimed的全资收购。此次战略收购标志着归创通桥加速国际化布局、提升全球竞争力的重要一步。Optimed成立于1985年，总部位于德国图特林根，专注于研发和生产用于外周血管疾病治疗的导管、球囊及支架等高端产品，在欧洲市场拥有稳固的渠道网络和良好的品牌声誉。通过此次收购，归创通桥不仅获得了Optimed成熟的研发平台与CE认证产品线，还进一步拓展了其在欧洲乃至全球的商业化能力。同时，双方在技术、供应链和临床资源方面的协同效应，有望推动创新产品的联合开发，加速国产高端医疗器械走向国际市场。归创通桥表示，未来将继续坚持‘自主研发+全球并购’双轮驱动战略，深化全球化运营，为全球患者提供更安全、高效的血管介入解决方案。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/15608.html